Another CME Tweetorial covering pan-tumor HER2 testing in advanced solid tumors!

Scroll down to read each Tweet of this CME Tweetorial on pan-tumor HER2 testing!

Click on each Tweet below to open on Twitter:
x.com/ASCP_Chicago/status/1840785569023995962

​Claim CME here: store.ascp.org/productlisting/productdetail?productId=172789750

2/18 HER2 now joins other tumor-agnostic biomarkers like MSI/MMR, Tumor Mutation Burden (TMB), NTRK, RET, BRAF V600E. Different testing methods such as IHC or NGS will detect different biomarkers.https://t.co/NjXRR6iOMx#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

4/18 HER2 is also called ERBB2. Testing by IHC detects HER2 expression while molecular testing by NGS detects HER2 amplification or activating mutations. HER2 expression and HER2 activating mutations are distinct molecular targets.#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

6/18 T-DXd is the first antibody drug conjugate (ADC) with a tumor agnostic approval to treat advanced solid tumors with HER2 overexpression (IHC 3+).https://t.co/7vohZuTuFW#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

8/18 Tumor heterogeneity can make HER2 interpretation challenging. Here’s an example of intratumoral HER2 heterogeneity. https://t.co/Cig40jNdv0#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

10/18 HER2 scoring criteria for gastric and GE cancers were published in 2016. Note the differences for biopsy vs. surgical specimens. https://t.co/97xeDbDoHV #HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

12/18 NGS may detect HER2 amplification. Most tumors with HER2 overexpression are likely to also exhibit HER2 amplification. https://t.co/SCQYvJqoyE#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

14/18 Here’s a table that lists how often we may see HER2 mutations, HER2 amplification, and HER2 overexpression in different tumors:https://t.co/rmlRr7CE1B#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

16/18 While IHC remains the clinical standard for pan-tumor HER2 testing, alternative methods are also being explored. Moreover, a growing area of research is detecting low levels of HER2 expression. This is clinically actionable in metastatic breast cancer.…

— ASCP (@ASCP_Chicago) September 30, 2024

18/18 Thank you for participating in this ASCP CME Tweetorial on pan-tumor HER2 testing! Claim your CME credit here: https://t.co/MJ8OJzFLhl#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

Claim CME here: store.ascp.org/productlisting/productdetail?productId=172789750